Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites
- 10 April 2012
- journal article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 84 (2), 215-223
- https://doi.org/10.1016/j.bcp.2012.04.001
Abstract
No abstract availableKeywords
Funding Information
- Cancer Council NSW
This publication has 43 references indexed in Scilit:
- DrugBank 3.0: a comprehensive resource for 'Omics' research on drugsNucleic Acids Research, 2010
- Structure and mechanism of the complex between cytochrome P4503A4 and ritonavirProceedings of the National Academy of Sciences of the United States of America, 2010
- A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2010
- Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastomaJournal of Neuro-Oncology, 2010
- Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular CarcinomaJNCI Journal of the National Cancer Institute, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid TumorsThe Oncologist, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Structural basis for ligand promiscuity in cytochrome P450 3A4Proceedings of the National Academy of Sciences of the United States of America, 2006
- In Vitro Prediction of the Terfenadine‐Ketoconazole Pharmacokinetic InteractionThe Journal of Clinical Pharmacology, 1994